

make life lively
meiji

Meiji Seika Pharma Co., Ltd.

Trade Name

Meiji Seika Pharma Co., Ltd.

Main Businesses

Manufacturing and sale of ethical pharmaceuticals,
 agricultural chemicals and veterinary drugs

Head Office

4-16, Kyobashi 2-chome, Chuo-ku, Tokyo 104-8002, Japan

President and Representative Director

Daikichiro Kobayashi

Established

October 9, 1916

Paid-in Capital

¥28.363 billion

Consolidated Annual Sales

(Fiscal year ended March 2015)

¥141.338 billion

Consolidated Number of Employees

(As of March 31, 2015)

5,565

<Reference>

Meiji Group Annual Sales

(Fiscal year ended March 2015)

¥1,161.152 billion

Number of Meiji Group Employees

(As of March 31, 2015)

16,559

Website Address

<http://www.meiji-seika-pharma.co.jp>



Meiji Seika Pharma Co., Ltd.

Helping people to enjoy healthier lives — We will contribute to society by earning the trust of all our customers

Meiji Seika Pharma Co., Ltd. handles businesses in speciality & generic pharmaceuticals, agricultural chemicals and veterinary drugs, and the Company is committed to fulfilling its social responsibilities by contributing to the users of its products, who include patients, healthcare practitioners, and agricultural producers, through research and development of effective and high-quality products, stable product supply, and the prompt provision of product information.

In all aspects of our operations—including R & D, manufacturing, quality control, logistics, sales and marketing, along with the provision of information—we demonstrate the Meiji Group philosophy of “meeting all expectations regarding Health and Reassurance.” Each and every member of our company is dedicated to helping people enjoy healthier lives.

We aim to be a pharmaceutical company that is trusted by users. For this purpose, all of our employees are to stay closely in tune with the feelings of patients and other users and work day in and day out with sincerity and humbleness so that they can use our products effectively and with reassurance.



Daikichiro Kobayashi
President and Representative Director
Meiji Seika Pharma Co., Ltd.

Meiji Group's System of Principles

Group Philosophy

Our mission is to widen the world of “Tastiness and Enjoyment” and meet all expectations regarding “Health and Reassurance.” Our wish is to be closely in tune with our customers’ feelings and to always be there to brighten their daily lives.

Our responsibility as “Food and Health” professionals is to continue finding innovative ways to meet our customers’ needs, today and tomorrow.

Management Attitude

Five Fundamentals

1. Commit ourselves to customer-based ideas and behaviors
2. Provide safe and reassuring high-quality products
3. Strive to always produce new value
4. Foster the development of the synergies and capabilities of the organization and each individual
5. Be a transparent, wholesome company trusted by the society

Action Guidelines

meiji way

In order to be an essential part of our customers, partners, and colleagues’ daily lives, we must:

1. Listen to and learn from our customers
2. Find ways to identify tomorrow’s trends and be prepared to lead the way
3. Make our work exciting, and create exciting work
4. Have the strength and courage to confront any issues, rather than to avoid them
5. Always believe in our team’s potential, and make the most of its abilities



Contributing to the well-being of people worldwide through Creation of Value by research and development of ethical pharmaceuticals, agricultural chemicals, and veterinary drugs, and by providing high-quality, low-priced generic drugs.

In order to protect people’s health and lives, Meiji Seika Pharma will focus on three main fields (anti-infective drugs, drugs for central nervous system (CNS) disorders, and generic drugs), aiming to become one of Japan’s leading companies in these fields. Also, it will contribute to society and gain the trust of patients, medical institutions, and users as a “Speciality & Generic Pharmaceuticals Company” that has the ability to expand business internationally and which facilitates safe, reliable food production and animal health.



Meiji Seika Pharma's overseas bases

Meiji Brand Logo



Logo mark symbolizing the Group Philosophy


The Meiji Brand Logo is to symbolize our hope that Meiji can be a constant, beloved presence in the lives of people of all ages, from infants to the elderly.

The usage of soft, rounded lower-case lettering represents the cheeriness befitting a corporate group in the “Food and Health” business, as well as the warm connection we have with each customer.

In particular, the shape of the letters “iji” can be seen to represent the outline of a group of people supporting one another, and the letter “e” appears to be smiling out at those people.

The Meiji Brand Logo is proof of our promise to put our Group Philosophy into practice.

Meiji Group Management Structure



Ethical Pharmaceuticals Business

We have been providing with various pharmaceuticals for over 60 years as the pharmaceutical business segment of Meiji Seika Kaisha, Ltd., our predecessor, since beginning production of penicillin in 1946. We will continue supporting people's health and lives as a "Speciality & Generic Pharmaceuticals Company."



Contributing to Society in the Fields of Infectious Diseases and CNS Disorders

Our pharmaceuticals business had a history of over 60 years since Meiji Seika Kaisha, Ltd., our predecessor began with its development of penicillin in 1946. Following commencing penicillin production, we started selling our "STREPTOMYCIN Meiji" for tuberculosis treatment in 1950. We launched Japan's first internationally viable drug, "KANAMYCIN Meiji," in 1958. As Japan's top manufacturer of antibacterial drugs, we established our own manufacturing and development technologies, providing a series of excellent antibacterial drugs.

In 1990, we launched "HABEKACIN," the first MRSA infection treatment in Japan. In 1994, we launched our "MEIACT," an oral cephalosporin antibiotic that in 2009, we launched "ORAPENEM," the world's only oral carbapenem antibacterial drug. Progress and wider use of antibiotics has saved people suffering from infection, greatly contributing to longevity and health promotion. In contrast, there has been an increase in CNS disorders, as well as cardiovascular and metabolic disorders, due to various causes, such as advent of the aging society in Japan, changing of living environments and stress. In response to these medical needs, in the CNS field, we launched our "MEILAX," an anti-anxiety medication, in 1989 and "DEPROMEL," antidepressant, in 1999. In 2005, "DEPROMEL" became the first drug treatment approved for Social Anxiety Disorder (SAD) in Japan, greatly contributing to the treatment of such mental disorders.

In 2009, we launched "REFLEX," an unique noradrenergic and specific serotonergic antidepressant (NaSSA), in Japan. Based on two antidepressants with different mechanisms and an anti-anxiety drug etc., we aim to become a leading company in the depression and other CNS disorders.

Speciality & Generic Pharmaceuticals Company

Applying our know-how cultivated in the new drugs business, Meiji Seika Pharma leads other companies has been working to develop its generic pharmaceuticals business as a "Speciality & Generic Pharmaceuticals Company." In the generic business, we have been quick to establish an organization which centralizes the functions of business planning, drug research, product development and sales, while simultaneously making more strenuous efforts on quality assurance, information provision and a stable supply. While we are strengthening our generic drug pipeline with a main focus on infectious diseases and CNS disorders, the mainstay fields in our speciality drugs business, we are providing highly convenient and high-quality "useful generics," as well to meet diverse medical needs.

Creations for the Brilliant Future

Aiming to meet diversified medical needs, Meiji Seika Pharma is building new R&D technical basis and is working on approaches for targeting new fields. We will continue drug discovery research initiatives in the infectious diseases field while advancing research in such new fields as biopharmaceuticals and regenerative medicine. We are also eagerly working to develop treatments for unmet medical needs, and for cancer and other intractable diseases. To further expand and enhance our generic drugs business, we are also investing strong efforts in biosimilars. In this way, Meiji Seika Pharma is working to evolve its "Speciality & Generic" model in its ethical pharmaceuticals business.

Drug Fostering & Evolution through the Sharing of Information

In addition to providing information on the Company's products, medical representatives (MRs) make efforts to obtain information on drug effectiveness and safety that was unavailable at the R&D stage by conducting post-marketing surveillance. MRs gather information on cases in which various side effects have been identified, including serious side effects and any unknown side effects. MRs are responsible for reporting this information to the Company.

MRs collect up-to-date information regarding the most recent cases from medical institutions, and report those information to the pharmacovigilance department. Based on the compiled results of case analyses conducted by this department, MRs then provide information to medical institutions concerning more effective and safe appropriate-use methods. By ensuring that the correct prescriptions reach a greater number of patients, the value of pharmaceuticals increases, and also life cycle of products extends. MRs also play a vital role by identifying user needs at medical facilities, and providing feedback to the R&D departments, which leads to new drug development and improvements in existing drugs.

Providing and Collecting High Quality Information throughout Japan


At Meiji Seika Pharma, MRs are assigned to university hospitals, local hospitals and general practitioners in each region of Japan. MRs are responsible for promoting the use of our Company's ethical pharmaceutical products, while some MRs are dedicated to promoting the use of CNS drugs in medical speciality, such as in psychiatric and psychosomatic departments of hospital, and mental health clinics. Our MRs work closely with medical staff and patients, in both providing and collecting information.

We have built as an MR information provision support system and a pharmaceutical information search database for MR promotion activities in each region throughout Japan. Under this system, MRs can use iPads and mobile PCs to provide and obtain the required information in a timely manner.

Enhancing MR Education and training to Contribute to Advances in Medical Care

Meiji Seika Pharma provides continuing education and training to maintain and enhance the levels of expertise of its MRs. The curriculum covers knowledge of product characteristics, details regarding diseases, drug treatment and pharmaceuticals, and the ethics, laws and regulations, etc., Those are required for medical professionals.

New employees are given training, which covers basic knowledge on medicine, pharmacology and the Company's products, and aim to enhance their business negotiation skills and other skills they will require as MRs. We are also creating our training program for supporting our employees to pass the MR Accreditation Test administered by the MR Education and Accreditation Center of Japan.



Medical Representative Activities

Pharmaceuticals can be used effectively only if accurate information regarding effectiveness and safety considerations is simultaneously provided. Through its medical representative (MR) activities, Meiji Seika Pharma provides information on the effectiveness and safety considerations of pharmaceuticals, as well as other high-value-added information, supporting the health of people.



Agricultural Chemicals and Veterinary Drugs Business

Through its agricultural chemicals and veterinary drugs businesses, Meiji Seika Pharma contributes to the stable supply of safe and reliable agricultural, livestock and marine products and also improve productivity in these industries, that can support people's lives worldwide.



Agricultural Chemicals and Veterinary Drugs Businesses for Food Safety and Stable Supply

Since we launched the "GIBBERELLIN" plant growth regulator in 1961, the agricultural chemicals business has commenced the sale of products such as the "AGREPT" garden bactericide, and has been steadily expanding its business operations. "ORYZEMATE," a rice blast preventative and one of our mainstay products, over 40 years and it has been highly regarded by agricultural producers, boasting the top sales in the rice paddy field.

We are working to build the foundations for expansion of our agricultural chemicals business, through "ZAXA," a new liquid formula herbicide, which we obtained the product registration for and launched in March 2011.

In our veterinary drugs business, we are creating a product line to meet diverse needs in the livestock and fisheries industries. We have widened our activities by entering related areas such as feed additives, disinfectants and vaccines, and have established a No. 1 position in these areas today.

We are also actively developing business in the companion animal (CA) field, working to promote the health of small animals with drugs and nutritional supplements. We boasted the top market share in environmental disinfectants for cattle barns and poultry houses, which are effectively applied in case of outbreaks of foot and mouth disease or bird flu, etc. We will continue undertaking active business development as a leading company in veterinary drugs.

Pipelines in the Agricultural Chemical and Veterinary Drugs Business

In the agricultural chemicals business, we are implementing official field trial for registration with a view to applying for the registration of multiple new insecticides.

Further, in May 2010 we entered into a licensing agreement with BASF SE, of Germany, for an agriculture insecticide under development. We aim to bring this next-generation insecticide—which promises to be environment friendly and highly safe—to the global market as soon as possible. In addition, in July 2013 we concluded an agreement with Dow AgroSciences LLC, of the United States, for the co-development and commercialization of a fungicide for agrochemical use that has a new mechanism of action against wheat pathogens. The veterinary drugs business is expanding and improving its product lineup by promoting the development of drugs of livestock animal, companion animal, and other veterinary drugs.

Growth Strategy in the Agricultural Chemical and Veterinary Drugs Business

In the agricultural chemicals business, we will maintain our leading market share in the domestic rice cropping sector centered on "ORYZEMATE." At the same time, we will continue expanding and enhancing our product lineup through the discovery of new chemicals and set our sights on developing businesses in Japan and overseas.

In the veterinary drugs business, livestock and fisheries field as our core, in which we boast one of the top market shares in Japan. We are also strengthening our CA field product lines, as we pursue expansion overseas with a focus on the expanding Asian market.

Through its agricultural chemicals and veterinary drugs businesses, Meiji Seika Pharma will continue contributing to the safe and stable supply of food in Japan and abroad.

Expanding Overseas, especially in Asian Growth Markets

We began exporting an antibacterial drug in 1954, and currently ship "meiji" brand pharmaceuticals, including "MEIACT" and "FOSMICIN," to countries. Accompanying advances in this business field, the Company expanded operations, beginning in Indonesia with the founding of P.T. Meiji Indonesian Pharmaceutical Industries in 1974, followed by Thai Meiji Pharmaceutical Co., Ltd. in Thailand in 1979, which manufacture and sell pharmaceuticals and veterinary drugs in their respective countries, thereby contributing to local medical care, and serving as pharmaceutical and veterinary drug production bases for Japan and other countries.

In recent years, we have put particular effort into enhancing the manufacturing facilities at P.T. Meiji Indonesian Pharmaceutical Industries, and are working to establish the company as a production base for penicillin-based antibacterial drugs, which GMP standards for manufacturing and quality control require to be produced on separate production lines from other pharmaceuticals. By establishing a high-quality and reliable production system for penicillin and enhancing cost competitiveness, this subsidiary will be able to undertake contract manufacturing of penicillin for other companies. In addition, Meiji Seika Pharma is responding to the growing demand of generic drugs by enhancing production capabilities for generic drugs at Thai Meiji Pharmaceutical Co., Ltd. and bulk materials for such generic drugs at Meiji Pharma (Shandong) Co., Ltd. in China.

In China, which is expected to be the largest market for global development, Shantou Meiji Pharmaceuticals Co., Ltd. was established in 1989 to manufacture and sell antibacterial drugs, anticancer drugs, and other products. Business operations in the Chinese market were boosted in 2004 with the addition of Meiji Lukang Pharmaceutical Co., Ltd. (currently Meiji Pharma (Shandong) Co., Ltd.), to support business expansion and to serve as a base for bulk drugs production by fermentation. We established a business development base for growth in the European market in 1991 with the founding of Tedec-Meiji Farma, S.A. in Spain, and it is expanding its business in Europe.

In 2015, Medreich Limited of India joined the Group. We are building new business foundations for the CMO (contract manufacturing organization) and CDMO (contract development and manufacturing organization) businesses based on economical drug production.

Meiji Seika Pharma Co., Ltd., aims to be a corporate group that contributes to the health of people worldwide and which develops internationally as a "Speciality & Generic Pharmaceuticals Company."



International Business

Aiming to raise the profile of the Meiji brand internationally and establish it as a global brand, we are enhancing the manufacturing and sales of our local subsidiaries. We are also actively developing our businesses on a licensing basis, building collaborative systems with sales partners.





Research and Development

At Meiji Seika Pharma, the R&D organization is composed of the Pharmaceuticals Research Center, the CMC Research Laboratory, the Bioscience Laboratory, and the Agricultural & Veterinary Research Laboratory. These laboratories conduct a wide range of R&D activities with the objective of becoming a speciality pharmaceutical company in the field of infectious diseases and CNS disorders, and also focus on generic drugs, agricultural chemicals, and veterinary drugs.

We believe a key strategy for strengthening the bases for these operations is to increase the number of product candidates in the product pipeline.

Regarding research and development of ethical pharmaceuticals, we are taking a short-, medium- and long-term perspective as we construct an R&D portfolio with diversified risk, which includes in-house drug discovery research and encompasses product lifecycle management (including indication expansion, new uses, new route of administration and drug formulations) and the development

of in-licensing products.

As a new approach in our core area of drugs for infectious diseases, we are adopting a long-term view in research and development.

We are conducting biopharmaceutical R&D through DM Bio Limited, jointly established with Dong-A Socio Holdings Co., Ltd., in South Korea in 2013. Further, our Bioscience Laboratories are advancing biological research based on knowledge and technology fostered through R&D on useful substances from microorganisms metabolites.

Furthermore, we have set up a representative office in the United States to conduct clinical research, so that we can develop in-house drug candidates and find partners for global development. Our goal is to ensure continued growth of our business as a "Speciality & Generic Pharmaceuticals Company".



Production

Meiji Seika Pharma strictly controls manufacturing of its pharmaceuticals, employing a quality control system that covers ingredient checking, manufacturing, packaging and shipping based on GMP standards. In the production of high-quality pharmaceuticals, the most important thing is the spirit of the employees. Each and every employee engages in pharmaceutical production with the strong desire of "wanting to ensure the quality of pharmaceuticals which will be delivered to patients," so that they can be used with confidence.

We also ensure a high level of quality assurance in the manufacturing of agricultural chemicals and other non-pharmaceutical products, utilizing our know-how from pharmaceuticals.

Manufacturing safe and reliable pharmaceutical products requires the use of advanced equipment and an ultra-clean manufacturing environment. This is why all our pharmaceutical plants have installed computerized manufacturing control systems, employing the latest GMP procedures.

We have advanced manufacturing facilities, and each and every employee is strongly committed to further raising quality and ensuring the delivery of consistently high-quality products to medical care facilities.

Reliability & Quality Assurance

Pharmaceuticals, which affect people's health and lives, require high-level quality assurance and safety management systems.

In compliance with Pharmaceuticals and Medical Devices Act, Meiji Seika Pharma appoints a marketing supervisor-general, a quality assurance manager, and a safety management supervisor, as well as establishing a "Reliability & Quality Assurance Division," comprised of quality assurance department, quality management department, and pharmacovigilance department. These form an organizationally and functionally unified system for the quality assurance and Regulatory Affairs Division, as well as pharmaceutical compliance, and serve to enhance and strengthen the reliability of our pharmaceuticals.

Our pharmaceutical plants comply with Good Manufacturing Practice (GMP) and Good Quality Practice (GQP) standards. Strict quality control is performed by a quality assurance department, which is independent from the production department.



Meiji Group's Approach to CSR

Our target profile— a corporate group essential to and trusted by its stakeholders

The basis of "the Meiji Group's Approach to CSR" is to fulfill corporate social responsibility (CSR) by putting the Group Philosophy into practice on a day-to-day basis in mainstay businesses and by remaining a corporate group society needs. Each Meiji Group employee will advance activities based on the Meiji Group's System of Principles and the Stakeholder Policy to meet stakeholders' expectations and continue fulfilling social responsibilities.

Our customers


We provide high-quality, safe products and services to meet customers' expectations in relation to health and reliability. Through these efforts, we improve the lifestyles of our customers.

Global environment

We appreciate the bounty of nature. Therefore, we protect natural resources and harmonize our business operations with the global environment to contribute to society's sustainability.

Employees

We respect the diversity and individuality of employees and develop safe and comfortable workplace environments. We believe dynamic communication is essential and establish creative and vibrant workplaces.



Society

We believe respecting human rights and communicating with society are important. As a good corporate citizen, we enrich customers' lives by providing Tastiness, Enjoyment, Health and Reassurance.

Shareholders and investors

We conduct sound, transparent business management. We communicate with shareholders and investors and disclose information in a timely, appropriate manner.

Business partners

We develop strong relationships with business partners based on mutual trust and communication. We are committed to fair, transparent, and free competition and procurement that is environmentally and socially responsible.

Group History

The Meiji Group's 100th anniversary in 2016

- | | |
|---|---|
| <p>1906 ● The former Meiji Sugar Co., Ltd. (hereinafter "Meiji Sugar"), the forerunner of the Meiji Group is established.</p> <p>1916 ● Tokyo Confectionery Co., Ltd. (hereinafter "Tokyo Confectionery"), the predecessor of Meiji Seika, is established.</p> <p>1917 ● Tokyo Confectionery merges with Taisho Seika, a subsidiary of Meiji Sugar.</p> <p>1924 ● Tokyo Confectionery changes its name to Meiji Seika Kaisha, Ltd. (hereinafter "Meiji Seika").</p> <p>1946 ● The pharmaceuticals business is launched with the commencement of penicillin production.</p> <p>1950 ● The antibacterial drug "STREPTOMYCIN MEIJI" is introduced.</p> <p>1954 ● The antibacterial drug "CYCLIN MEIJI" is introduced.
● Exports of antibacterial drugs are commenced.</p> <p>1955 ● The veterinary penicillin-based feed additive "MEIRICH P" is introduced.</p> <p>1958 ● Japan's first world-class antibacterial drug "KANAMYCIN MEIJI" is introduced.</p> <p>1961 ● The plant growth promoter "GIBBERELLIN" is introduced.
● Activities at the Central Research Center (currently the Pharmaceuticals Research Center, CMC Laboratory, and Bioscience Laboratory) are commenced.
● The topical antiseptic "ISODINE" is introduced.</p> <p>1963 ● The agricultural chemical "AGREPT" is introduced.</p> <p>1969 ● The antibacterial drug "KANENDOMYCIN" is introduced.
● The veterinary antibiotic (gastrointestinal parasiticide) "DESTONATE" is introduced.</p> <p>1971 ● Operation of the Gifu Plant is commenced.</p> <p>1974 ● The antibacterial drug "MEDEMYCIN" is introduced.
● The joint venture P.T. Meiji Indonesian Pharmaceutical Industries is established.</p> <p>1975 ● The antibacterial drug "PANIMYCIN" is introduced.
● The agricultural chemical product "ORYZEMATE" is introduced.</p> <p>1976 ● Operation of the Kitakami Plant is commenced.</p> <p>1979 ● The feed additive "COLISTIN" is introduced.
● The joint venture Thai Meiji Pharmaceutical Co., Ltd. is established.
● Receives the Okochi Memorial Technology Award for the "Development and Mass Production of ORYZEMATE."</p> <p>1981 ● The antibacterial drugs "FOSMICIN" is introduced.</p> | <p>1987 ● The antibacterial drug "MEICELIN" is introduced.</p> <p>1988 ● The anticancer drug "THERARUBICIN" is introduced.</p> <p>1989 ● The anti-anxiety drug "MEILAX" is introduced.
● Kamei Pharmaceuticals (currently Shantou Meiji Pharmaceuticals Co., Ltd.) is established in China.
● The Odawara Plant commences production operations as a pharmaceuticals plant.</p> <p>1990 ● The antibacterial drug "HABEKACIN" is introduced.</p> <p>1991 ● Enters into capital participation in Tedec Zambelletti (currently Tedec-Meiji Farma, S.A.).</p> <p>1994 ● The antibacterial drug "MEIACT" is introduced.</p> <p>1998 ● Enters into capital participation in Kitasato Pharmaceutical Industry Co., Ltd. Generic Development Department is established and full-fledged entry to the generic drug market is commenced.</p> <p>1999 ● The antidepressant "DEPRONEL" is introduced.</p> <p>2002 ● Operations of the Microbiological Research Center (currently the Bioscience Laboratory) are commenced.
● The antibacterial drug "OMEGACIN" and the synthetic antibacterial drug "SWORD" are introduced.</p> <p>2003 ● Meiji Lukang Pharmaceutical Co., Ltd., (currently Meiji Pharma (Shandong) Co., Ltd.) is established.</p> <p>2004 ● The photosensitizing agent "LASERPHYRIN" is introduced.</p> <p>2009 ● In April, Meiji Seika and Meiji Dairies Corporation (hereinafter "Meiji Dairies") establish a joint holding company "Meiji Holdings Co., Ltd." (hereinafter "Meiji Holdings") and integrate the management.
● The antibacterial drug "ORAPENEM" is introduced.
● The antidepressant drug "REFLEX" is introduced.</p> <p>2010 ● Ohkura Pharmaceutical Co., Ltd. is transferred from Meiji Dairies Corporation.
● Prepares the Meiji Group 2020 Vision as a long-term business management strategy.</p> <p>2011 ● In April, Meiji Holdings reorganizes Meiji Seika and Meiji Dairies; Meiji Co., Ltd., a food company, and Meiji Seika Pharma Co., Ltd., a pharmaceuticals company, begin operation.
● The liquid formula "ZAXA" herbicide is introduced.</p> <p>2012 ● Treatment for COPD(Chronic Obstructive Pulmonary Disease) "OXIS" is introduced.
● Treatment for Dravet syndrome "DIACOMIT" is introduced.</p> <p>2013 ● Joint venture DM Bio Limited is established in South Korea.</p> <p>2015 ● β-lactamase inhibitor OPO595 is licensed out to F. Hoffmann-La Roche Ltd. (Switzerland).
● Medreich Limited of India joins the Group.</p> |
|---|---|

Operating Bases and Group Companies

In order to actively meet medical needs as a "Speciality & Generic Pharmaceuticals Company," and contribute to food safety and reassurance through our agricultural chemicals and veterinary drugs businesses, we provide a stable supply of high-quality Meiji brand products via our domestic and overseas networks.

Japan

■ Head Office

■ Branches

[Pharmaceuticals]

- Pharmaceuticals Sapporo Branch
- Pharmaceuticals Sendai Branch
- Pharmaceuticals Tokyo Branch
- Pharmaceuticals Chiba & Saitama Branch
- Pharmaceuticals Yokohama Branch
- Pharmaceuticals Kanto Branch
- Pharmaceuticals Nagoya Branch
- Pharmaceuticals Kyoto Branch
- Pharmaceuticals Osaka Branch
- Pharmaceuticals Chugoku Branch
- Pharmaceuticals Shikoku Branch
- Pharmaceuticals Fukuoka Branch

[Agricultural Chemicals]

- Agricultural Chemicals Sapporo Branch
- Agricultural Chemicals Sendai Branch
- Agricultural Chemicals Tokyo Branch
- Agricultural Chemicals Nagoya Branch
- Agricultural Chemicals Osaka Branch
- Agricultural Chemicals Kumamoto Branch

[Veterinary Drugs]

- Veterinary Drugs North Japan Branch
- Veterinary Drugs Tokyo Branch
- Veterinary Drugs Nagoya Branch
- Veterinary Drugs Osaka Branch
- Veterinary Drugs Kumamoto Branch

■ Research Laboratories

- Pharmaceuticals Research Center
- CMC Laboratory
- Bioscience Laboratory
- Agricultural & Veterinary Research Laboratory

■ Plants

- Kitakami Plant
- Odawara Plant
- Gifu Plant

■ Group Companies

- Kitasato Pharmaceutical Industry Co., Ltd.
- Ohkura Pharmaceutical Co., Ltd.
- Miyako Yuso Transportation Co., Ltd.

Overseas

■ Offices

- ① Madrid Office
- ② Beijing Office
- ③ U.S. Office

■ Group Companies

- ④ Meiji Pharma (Shandong) Co., Ltd.
- ⑤ Shantou Meiji Pharmaceuticals Co., Ltd.
- ⑤-2 Guangdong Meiji Pharmaceutical Co., Ltd.
- ⑥ Meiji Pharma Korea Co., Ltd.
- ⑦ P.T. Meiji Indonesian Pharmaceutical Industries
- ⑧ Thai Meiji Pharmaceutical Co., Ltd.
- ⑨ Medreich Ltd.
- ⑨-2 Genovo Development Services Limited
- ⑨-3 Adcock Ingram Limited
- ⑨-4 Medreich Life care Limited
- ⑨-5 Medreich Plc.
- ⑨-6 Medreich SA (Proprietary) Limited
- ⑨-7 Medreich Australia Pty Ltd.
- ⑨-8 Pharmazen Medicals Pte Ltd.
- ⑨-9 Medreich Far East Limited
- ⑨-10 Inopharm Limited
- ⑨-11 Medreich New Zealand Limited
- ⑩ Tedec-Meiji Farma, S.A.
- ⑩-2 Mabo Farma, S.A.
- ⑪ Meiji Seika Europe B.V.

